HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, Inc., a therapeutic oncology company, today announced the installation of its RefleXion® X1 platform at Smilow Cancer Hospital, part of Yale New Haven Health, Connecticut’s largest healthcare system. SCINTIX™ biology-guided radiotherapy, cleared by the U.S. Food & Drug Administration (FDA) in Feb. 2023, for treating tumors arising from primary or metastatic lung and bone cancers, will be installed as part of the integration, with patient treatments expected to begin in the next several months.
“Our hope is that SCINTIX therapy will allow us to expand the reach of radiotherapy as an option for patients with metastatic cancer and combine it with other treatments to improve outcomes for our patients,” said Peter Glazer, M.D., Ph.D., chair of the Department of Therapeutic Radiology at Yale School of Medicine and chief of Radiation Oncology at Smilow Cancer Hospital at Yale New Haven. “Currently, treating multiple solid tumors with radiotherapy entails a workflow that is operationally impracticable and very difficult, if not impossible, for patients. With SCINTIX therapy, we will have the ability to treat one or multiple sites of disease in the same treatment session while minimizing delivery of radiation to surrounding healthy tissue.”
SCINTIX therapy is the first and only radiotherapy that allows each cancer’s unique biology to autonomously determine where to deliver radiation, second by second, during actual treatment delivery. This expands the RefleXion X1 into the only dual-treatment modality platform that can treat patients with indicated solid cancerous tumors of any stage, including stage 4 cancer.
The SCINTIX biologic modality tracks tumor motion from all types of movement, including expected motion from internal processes such as breathing and digestion or unexpected movement by a patient. The X1 also has a state-of-the-art anatomic modality previously cleared by the FDA for solid tumors located anywhere in the body.
About RefleXion Medical
RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel treatment modality that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to multiple cancerous tumors. Granted Breakthrough Device designation for lung tumors and De Novo marketing authorization by the FDA, SCINTIX therapy is indicated for use in lung and bone tumors. These tumors may arise from primary lung and bone cancers or result from metastases to the lungs or bone from other primary cancers. The RefleXion X1 is also cleared for stereotactic body radiotherapy, stereotactic radiosurgery, and intensity modulated radiotherapy for solid tumors located anywhere in the body.Back to HCB News